Literature DB >> 7082539

Rapid reduction of blood pressure with acute oral labetalol.

A B Davies, V Bala Subramanian, B Gould, E B Raftery.   

Abstract

1 The effect of acute oral administration of labetalol on intra-arterial pressures in a group of ten hypertensive patients has been evaluated. 2 A single dose of 200 mg labetalol produced a significant reduction in systolic and diastolic pressures within 1 h of administration. 3 Within 24 h of initial administration, 200 mg three times daily produced a significant reduction in ambulant arterial levels of systolic pressure for 21 h and diastolic pressure for 14 h in the day. 4 Acute therapy lowered resting levels but there was no significant reduction in systolic pressure during either isometric or dynamic exercise. 5 Acute therapy was not associated with any significant postural hypotension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082539      PMCID: PMC1402081          DOI: 10.1111/j.1365-2125.1982.tb01440.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Combined alpha- and beta-adrenoreceptors blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise.

Authors:  G Koch
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

2.  Deoxycorticosterone excretion in normal, hypertensive and hypokalaemic subjects.

Authors:  C L Cope; S Loizou
Journal:  Clin Sci Mol Med       Date:  1975-02

3.  New system for recording ambulatory blood pressure in man.

Authors:  M W Millar-Craig; D Hawes; J Whittington
Journal:  Med Biol Eng Comput       Date:  1978-11       Impact factor: 2.602

4.  Labetalol in hypertension.

Authors: 
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321

5.  The methodology of blood pressure recording.

Authors:  E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

6.  Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.

Authors:  J Mehta; J N Cohn
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

7.  Cerebral complications in the treatment of accelerated hypertension.

Authors:  J G Ledingham; B Rajagopalan
Journal:  Q J Med       Date:  1979-01

8.  Rate of onset of hypotensive effect of oral labetalol.

Authors:  M J Serlin; M C Orme; M Maciver; G J Green; C M Macnee; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

9.  Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.

Authors:  J B Farmer; I Kennedy; G P Levy; R J Marshall
Journal:  Br J Pharmacol       Date:  1972-08       Impact factor: 8.739

10.  Labetalol in resistant hypertension.

Authors:  H J Dargie; C T Dollery; J Daniel
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

View more
  4 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 2.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 3.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.